Deutsche Bank AG Purchases New Position in CeriBell (NASDAQ:CBLL)

Deutsche Bank AG acquired a new stake in CeriBell (NASDAQ:CBLL - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 230,787 shares of the company's stock, valued at approximately $5,973,000. Deutsche Bank AG owned about 0.64% of CeriBell at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Legal & General Group Plc bought a new stake in shares of CeriBell during the 4th quarter worth approximately $32,000. Summit Investment Advisors Inc. purchased a new position in shares of CeriBell in the 4th quarter valued at $33,000. Tower Research Capital LLC TRC purchased a new position in shares of CeriBell in the 4th quarter valued at $37,000. BNP Paribas Financial Markets purchased a new position in shares of CeriBell in the 4th quarter valued at $43,000. Finally, PNC Financial Services Group Inc. purchased a new position in shares of CeriBell in the 4th quarter valued at $47,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CBLL. LADENBURG THALM/SH SH began coverage on CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 price target on the stock. Canaccord Genuity Group reissued a "buy" rating and issued a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $32.50.

CeriBell Stock Down 3.9%

Shares of CeriBell stock traded down $0.68 during trading on Friday, reaching $16.58. The company's stock had a trading volume of 211,770 shares, compared to its average volume of 277,143. The company has a 50-day simple moving average of $17.15 and a two-hundred day simple moving average of $22.11. CeriBell has a 1-year low of $10.01 and a 1-year high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. The firm had revenue of $20.49 million for the quarter, compared to analyst estimates of $19.30 million. Equities research analysts forecast that CeriBell will post -2.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Xingjuan Chao sold 5,700 shares of the business's stock in a transaction dated Thursday, April 17th. The stock was sold at an average price of $15.02, for a total value of $85,614.00. Following the completion of the transaction, the chief executive officer now owns 746,451 shares of the company's stock, valued at $11,211,694.02. The trade was a 0.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders sold 49,700 shares of company stock valued at $796,434. 20.10% of the stock is owned by company insiders.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.